Preference pioneers

Rituxan Hycela subcutaneous rituximab provides the first example of how companies can get patient preference data on an FDA-approved drug label.

The new formulation is intended to reduce the treatment burden of rituximab therapy, which was previously available only as an IV infusion that took 1.5-6 hours. The subcutaneous formulation can be administered by a healthcare professional in 5-7 minutes. ...